XML 75 R49.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies - Concentrations and Significant Customer Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Investment Concentration Risk        
Cash, cash equivalents and investments $ 466,300      
Investment in institutional money market funds 73,700      
Cash and cash equivalents 228,705 $ 119,296 $ 26,986 $ 46,293
Amount invested in a single fund 40,700      
Concentrations and Significant Customer Information        
Accounts receivable, net $ 85,678 $ 38,172    
Minimum        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 10.00%      
Sales Revenue, Net | Customer Concentration Risk | Amerisource Bergen Drug Corporation        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 25.00% 34.00% 41.00%  
Sales Revenue, Net | Customer Concentration Risk | Takeda Pharmaceutical Company Limited        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 12.00% 11.00% 11.00%  
Sales Revenue, Net | Customer Concentration Risk | McKesson Corporation        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 11.00% 21.00% 24.00%  
Sales Revenue, Net | Customer Concentration Risk | Cardinal Health Inc        
Concentrations and Significant Customer Information        
Concentration risk (as a percent)   15.00% 16.00%  
Sales Revenue, Net | Customer Concentration Risk | Cardinal Health Inc | Maximum        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 10.00%      
Sales Revenue, Net | Customer Concentration Risk | Group Purchasing Organization        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 26.00% 26.00% 30.00%  
Sales Revenue, Net | Geographic Concentration Risk        
Concentrations and Significant Customer Information        
Approximate percentage of revenues from customers outside the U.S. 12.00% 12.00% 11.00%  
Accounts Receivable | Customer Concentration Risk | Amerisource Bergen Drug Corporation        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 43.00% 45.00%    
Accounts Receivable | Customer Concentration Risk | McKesson Corporation        
Concentrations and Significant Customer Information        
Concentration risk (as a percent)   12.00%    
Accounts Receivable | Customer Concentration Risk | McKesson Corporation | Maximum        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 10.00%